The effect of brotowali (*Tinospora crispa L.*) stem ethanolic extract on the inhibition of *Candida albicans* biofilm formation

Suryani Hutomo1, Christiane Marlene Sooa2, Maria Silvia Merrey1, Ceny Gloria Larope3, Haryo Dimasto Kristiyanto1

1Department of Microbiology, Faculty of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia
2Department of Parasitology, Faculty of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia
3Undergraduate student, Faculty of Medicine, Duta Wacana Christian University, Yogyakarta, Indonesia

ABSTRACT

**Background:** *Candida albicans* (*C. albicans*) is an opportunistic pathogen that can be found in the oral cavity and other parts of the body. This species is the main cause of oral candidiasis and forms a biofilm as its virulence factor. Due to increasing cases of antifungal resistance, research is needed on methods to control Candida biofilm formation. Brotowali (*Tinospora crispa L.*) is known to be antifungal, antiseptic and antiparasitic. **Purpose:** The purpose of this study is to analyse the ability of brotowali stem extract to inhibit *Candida* biofilm formation. **Methods:** The susceptibility of *C. albicans* to this extract was examined by a minimum inhibitory concentration (MIC) test using the broth microdilution method. A bacterial adherence assay was performed by similar methods of the MIC assay. A brotowali stem extract of various concentrations were incubated in a yeast peptone dextrose broth medium and stimulated with a *C. albicans* suspension. The 0.1% crystal violet was used to stain the adherent fungi and measured using a microplate reader at 595 nm. Scanning electron microscopy (SEM) was performed to provide a general overview of the biofilm formation. **Results:** The MIC value for the brotowali stem extract was at a concentration of 5,000 μg/ml. Moreover, this extract inhibited fungal adherence starting at a concentration of 250 μg/ml. Observation using SEM confirmed these results. Statistical analysis using one-way analysis of variance demonstrated a significant difference of *C. albicans* adherence following stimulation with brotowali extract (p < 0.005). **Conclusion:** Brotowali stem extract can inhibit *C. albicans* biofilm formation at an optimal concentration of 1,000 μg/ml.

**Keywords:** adherence; biofilm; *C. albicans*; *Tinospora crispa L.*

Correspondence: Suryani Hutomo, Department of Microbiology, Faculty of Medicine, Duta Wacana Christian University. Jl. Dr. Wahidin Sudirahusodo No. 5-25 Yogyakarta, 55224, Indonesia. Email: suryanihutomo_drg@yahoo.com

INTRODUCTION

*Candida albicans* (*C. albicans*), the most common type of *Candida* spp., is a normal flora of the human body. These fungi can turn into opportunistic pathogens that are responsible for mucosal infections, including oral and vaginal.1,2 *Candida albicans* is the main cause of 95% of oral candidiasis infections.3 Oral candidiasis can be found on the buccal mucosa, oropharynx and tongue.4 This species can change into opportunistic pathogens in immunocompromised hosts, patients with catheters, dental prostheses, and those who are taking long-term antibiotics causing superficial candidiasis and systemic candidiasis.5 The main predisposing factors for developing oral candidiasis are salivary dysfunction, poor denture hygiene, long-term prostheses, topical corticosteroid therapy and smoking.3 **Candida albicans** have distinctive characteristics that include morphological changes and biofilm formation. Its ability to grow into three different morphologies (yeast, pseudohyphae and true hyphae) contributes to biofilm formation,6 which makes the treatment of *C. albicans* challenging. The National Institute of Health reports that biofilms are responsible for more than 80% of microbial infections.7 These microbial infections are due to resistance to antifungal agents and increased pathogenicity of *C. albicans*.8 The biofilm’s extracellular matrix plays an essential role in the development of *C. albicans* resistance, as it serves as a physical barrier against drug penetration.9 In addition, it protects fungi from the innate immune system.
by killing neutrophils and monocytes. Previous studies have reported multiple cases of antifungal resistance, including Candida resistance to echinocandin drugs, such as micafungin, anidulafungin and caspofungin, and the azole, including fluconazole, itraconazole and isavuconazole. Therefore, the utilisation of antifungal agents should be minimised, and methods to control biofilm formation need to be developed.

Indonesia has around 30,000–50,000 species of plants, 7,500 of which have been used as medicinal plants. A well-known medicinal plant, brotowali (Tinospora crispa L.), is a wild vine that grows in Asian countries, including Indonesia. Extracts of its stem, root and leaves have been shown to have antifungal properties. More than 65 compounds were identified specifically from brotowali stems, such as flavones, alkaloids, berberine and diterpenes. The antifungal content of brotowali stems is derived from berberine alkaloids and flavonoids. In addition to its antifungal properties, it is analgesic, antipyretic, antiparasitic and antiseptic. This study aims to determine the ability of brotowali stem ethanolic extract to inhibit C. albicans biofilm formation.

MATERIALS AND METHODS

Candida albicans was obtained from a patient with candidiasis from Bethesda Hospital, in Yogyakarta, Indonesia. The fungi were isolated and identified using a CHROMagar Candida medium (Becton Dickinson, Germany). The colonies of C. albicans appeared to be light to medium green (Figure 1). After identification, two colonies of C. albicans were grown in a yeast peptone dextrose (YPD) broth medium (Sigma, Missouri, USA) for 24 h at 37°C. The concentration of stock suspension was prepared as a 0.5 McFarland.

The brotowali stem simplicia was obtained and confirmed by a botanical expert at the herbal manufacturing company, CV Merapi Farma, Yogyakarta, Indonesia (ref. 122/MFH-SIMP/IV/2021). The plants used in this study were grown in the village of Hargobinangun, Pakem, Sleman, Yogyakarta. The plants were cultivated in appropriate conditions for three months and their brown-black–coloured stems were obtained. The simplicia was processed into an ethanolic extract via a maceration technique (a modification of our previous study) in the biology laboratory of the Faculty of Pharmacy, Universitas Gadjah Mada Yogyakarta, Indonesia. The 1,000 g of simplicia was mixed with 1,000 ml ethanol 96% and stored at 4°C for 24 hours. The macerate was separated by filtration three times and concentrated by a vacuum rotary evaporator at 70°C to obtain an ethanolic extract of brotowali stem. The extract, in paste form, was stored in a refrigerator at 4°C until used. The paste was dissolved in a dimethyl sulfoxide 1% solution (DMSO, Merck, Germany) as a stock in a concentration of 10,000 μg/ml for the analysis of its fungal susceptibility and a concentration of 4,000 μg/ml for the adherence assay. The stock of the extract was filtered using a 0.45 μm syringe filter (Sartorius, Germany) before being diluted with the YPD broth.

The susceptibility of C. albicans to the brotowali stem extract was determined via a minimum inhibitory concentration (MIC) test using the broth microdilution method. Ten μl of 0.5 McFarland fungal culture was inoculated into 100 μl of YPD broth containing the brotowali stem ethanolic extract at a concentration ranging from 312.5 to 10,000 μg/ml in a 96-well culture plate (Iwaki, Japan). The experiments were performed by using three well replicates. Fluconazole (Dexa Medica Indonesia) was used as the standard antifungal agent at a concentration of 2,000 μg/ml. The plates were incubated for 24 h at 37°C and observed for the visual absence of turbidity. The MIC of the extract was defined as the lowest concentration that showed no turbidity.

The method used for fungal adherence assay was similar to the susceptibility assay. A 10 μl brotowali stem ethanolic extract at a concentration ranging from 250 to 4,000 μg/ml were added to the 100 μl YPD medium and incubated for 30 min at 37°C in a 96-well culture plate. The culture was stimulated with 10 μl of the 0.5 McFarland C. albicans suspension and incubated at 37°C for 24 hours. Following incubation, the YPD medium was removed from each well via washing with a phosphate buffer saline solution (PBS, Sigma-Aldrich, Germany) and fixed with 150 μl absolute methanol for 15 min. The adherent fungi on the wells were stained with 0.1% (wt/vol) crystal violet for 10 min at room temperature and rinsed with PBS twice. The stained, adherent fungi were extracted from the wells using 200 μl of 96% ethanol and transferred to a fresh 96-well plate. The absorbance of the stained adherent bacteria was measured at 595 nm using a microplate reader (Thermo Scientific, USA). The data were analysed via one-way analysis of variance (ANOVA) at a significance level of 0.05 with p < 0.05 considered significant. Data analysis was performed via GraphPad Prism (La Jolla, CA, USA).

A general overview of the bacterial adherence to the hydroxyapatite (HA) disks were performed using a scanning electron microscope (SEM). The HA discs

Figure 1. Candida albicans culture in CHROMagar medium.
(10mm in diameter and 1.2mm in thickness) were created by placing 500 mg of hydroxyapatite powder into a mould and compressed at 120 Mpa. Finally, the discs were sintered for two hours at 1,300°C and placed in the autoclave for 15 minutes at 100°C to achieve sterilisation.

The HA discs in the 500 μl YPD medium were incubated with 100 μl of the brotowali stem ethanolic extract at a concentration of 0 and 2,000 μg/ml for 30 min at 37°C in a 24-well culture plate (Iwaki, Japan). The culture was inoculated with 100 μl of the 0.5 McFarland C. albicans suspension and incubated at 37°C for 24 hours. Thereafter, the discs were rinsed twice with sterile PBS and placed in a primary fixative solution (glutaraldehyde 0.15 M 2.5% [vol/vol] in PBS) for 12 h at 4°C. The discs were rinsed with sterile PBS and treated with the secondary fixative (osmium tetroxide [OsO₄ 1% w/v]) for 1 hr. The discs were subsequently rinsed with distilled water, dehydrated in an ethanol series (70% for 10 min, 95% for 10 min, and 100% for 20 min) and air dried overnight in a desiccator. The discs were coated twice with platinum vanadium using a sputter ion (Bal-Tec SCD 005; BAL-TEC, Balzers, Liechtenstein) and bonded to carbon double-sided tape for examination via SEM (Hitachi SU3500, Japan).

**RESULTS**

The MIC value for the brotowali stem extract was at a concentration of 5,000 μg/ml. It was indicated by no turbidity in the YPD medium just as the fluconazole group as a standard of antibacterial agent (Figure 2). The data were representative of three times experiments.

The fungal adherence assay demonstrated that inhibition occurred at concentrations of 500, 1,000, 2,000 and 4,000 μg/ml and were characterised by a decreased optical density (OD) value compared with the control group. The OD value decreased proportionally with increasing extract concentrations, but at a concentration of 4,000 μg/ml, the OD values had values similar to those at a concentration of 2,000 μg/ml. There was no significant difference of the OD value between concentrations of 4,000 μg/ml and 2,000 μg/ml, as seen in Figure 3. The experiment was repeated three times to confirm the data. Statistical analysis via one-way ANOVA showed that there was a significant difference between groups ($p = 0.000$). The aim of this study was to inhibit C. albicans biofilm formation, and the optimum concentration of brotowali stem deleted extract was found to be 1,000 μg/ml.

![Figure 2. The fungal susceptibility. No treatment (I); the concentration ranging from 10,000 μg/ml (B) to 156.25 μg/ml (H). The MIC was at a concentration of 5,000 μg/ml (C, blue box); Fluconazole used as a standard of antifungal agent (A).](image)

![Figure 3. Optical density values of C. albicans adherence at various concentrations. Notes: ns: not significant; ***: $p < 0.001$.](image)
Berberine affects biofilm formation by reducing the thickness of the biofilm and destroying its structure. Berberine is able to suppress the dimorphic changes of *C. albicans*, thus inhibiting the development of biofilms. The mechanism of berberine as an antifungal agent occurs via the reduction of regulatory gene expression in biofilm formation and proliferation of hyphae. Berberine causes changes in the mitochondrial membrane potential ($\Delta \psi_m$). The role of mitochondria in fungi is essential in signaling the metabolic pathway during virulence and infection in the host and defense against oxidative stress. Changes in the mitochondrial membrane potential opens pores in the membrane, triggering the release of proapoptotic factors and resulting in fungal apoptosis. In addition, the combination of berberine and fluconazole accumulates mainly in the nucleus of *C. albicans* and cause DNA damage.

Flavonoids are secondary metabolites and the largest class of polyphenols widely found in plants. The antifungal activities of flavonoid occurs via several mechanisms, such as plasma membrane disruption, induction of mitochondrial dysfunction, inhibition of cell formation, protein synthesis and efflux pumps. Flavonoids such as quercetin can increase the production of farnesol, which suppresses biofilm formation and hyphae development in *C. albicans*. The combination of the flavonoid quercetin with fluconazole has the ability to prevent cell-to-cell communication, thereby disrupting gene expression in biofilm formation. In this study, it was hypothesised that alkaloid, berberine and flavonoid compounds in the brotowali stems inhibited fungal growth and the biofilm formation.

In this study, an HA disk was used as a medium for *C. albicans* adherence. However, these results had not yet represented the *C. albicans* adherence to mucosal surface. Future studies are recommended to analyse the ability of this extract to inhibit *C. albicans* adherence on mucosal surfaces.
epithelium. In conclusion, brotowali (*Tinospora crispa L.*) stems were found to have antifungal activity against *C. albicans*. We suggest that this extract may serve as a potential natural product for oral care medicaments to control *Candida* biofilm formation, particularly in immunocompromised hosts.

**ACKNOWLEDGEMENT**

The authors would like to thank the Faculty of Medicine, Universitas Kristen Duta Wacana, Yogyakarta, Indonesia for the grant that funded this research.

**REFERENCES**

1. Moyes DL, Naglik JR. Mucosal immunity and Candida albicans infection. Clin Dev Immunol. 2011; 2011: 346307.
2. Kadosh D. Regulatory mechanisms controlling morphology and pathogenesis in Candida albicans. Curr Opin Microbiol. 2019; 52: 27–34.
3. Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: A disease of opportunity. J fungi (Basel, Switzerland). 2020; 6(1): 15.
4. Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: An overview. J Oral Maxillofac Pathol. 2014; 18(Suppl 1): S81-5.
5. Kabir MA, Hussain MA, Ahmad Z. Candida albicans: A model organism for studying fungal pathogens. ISRN Microbiol. 2012; 2012: 383694.
6. Kim J, Sudbery P. Candida albicans, a major human fungal pathogen. J Microbiol. 2011; 49(2): 171–7.
7. Noble CJ, Johnson AD. Candida albicans biofilms and human Disease. Annu Rev Microbiol. 2015; 69: 71–92.
8. Lestari PE. Peran faktor virulensi pada patogenesis infeksi Candida albicans. Stomatognauc - J Kedokt Gigi. 2010; 7(2): 113–7.
9. Pereira R, Dos Santos Fontenelle RO, de Brito EHS, de Morais SM. Biofilm of Candida albicans: formation, regulation and resistance. J Appl Microbiol. 2021; 131(1): 11–22.
10. Ponde NO, Lortal L, Ramage G, Naglik JR, Richardson JP. Candida albicans biofilms and polymeric interactions. Crit Rev Microbiol. 2021: 47(1): 91–111.
11. Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis. 2015; 61(Suppl 6): S612-7.
12. Arendrup MC, Patterson TF. Multidrug-resistant Candida: Epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017; 216(Suppl 3): S445–51.
13. Aminul H, M IAS, Mohammad S. Antimicrobial, cytotoxicity and antioxidant activity of Tinospora crispa. J Pharm Biomed Sci. 2011; 13(12): 1–4.
14. Ahmad W, Jantan I, Bukhari SNA. Tinospora crispa (L.) Hook. f. & Thomson: A review of its ethnomedical, phytochemical, and pharmacological aspects. Front Pharmacol. 2016; 7: 59.
15. Zuza-Alves DL, Silva-Rocha WP, Chaves GM. An update on Candida tropicalis based on basic and clinical approaches. Front Microbiol. 2017; 8: 1927.
16. Hutomo S, Putri DU, Welviyanda BC, Susilowati H. Inhibition effect of garlic (Allium sativum) extract on Streptococcus sanguinis biofilm formation involving bacterial motility mechanism. Malaysian J Med Heal Sci. 2021; 17(2): 659–74.
17. Raja AF, Ali F, Khan IA, Showel AS, Arora DS. Acetyl-11-keto-b-boswellic acid (AKBA); targeting oral cavity pathogens. BMC Res Notes. 2011; 4: 406.
18. Siswomihardjo W, Sunarintyas S, Tontowi AE. The effect of zirconia in hydroxyapatite on staphylococcus epidermidis growth. Int J Biomater. 2012; 2012: 432372.
19. Setiawati S, Nuryastuti T, Ngirdjian D, Mustofa M, Jumina J, Fitrastuti D. In vitro antifungal activity of (1)-N-2-Methoxybenzyl-1,10-phenanthroline bromide against Candida albicans and its effects on membrane integrity. Mycobiology. 2017; 45(1): 25–30.
20. Warsinah, Harwoko, Nuryanti. Screening of volatile compounds of brotowali (*Tinospora crispa*) and antifungal activity against Candida albicans. Int J Pharmacogn Phytochem Res. 2015; 7(1): 132–6.
21. Inci M, Atabay MA, Özer B, Evrigen Ó, Duran N, Köksaldı Motor V, Koğ AN, Önlun Y, Kilinc Ç, Durmaz S. Investigations of ALS1 and HWP1 genes in clinical isolates of Candida albicans. Turkish J Med Sci. 2013; 43(1): 125–30.
22. Titts J, Cammee BPA, Thevissen K. Combination therapy to treat fungal biofilm-based infections. Int J Mol Sci. 2020; 21(22): 8873.
23. Huang X, Zheng M, Yi Y, Patel A, Song Z, Li Y. Inhibition of berberine hydrochloride on Candida albicans biofilm formation. Biotechnol Lett. 2020; 42(11): 2263–9.
24. Burbunnadun B, Karta IW, Tresnanda B, Putra IGND, Darmada IPA, Pradnyadhita, IIDA, Gunawan IWBA, Ariawan IMB. Daya hambat vitamin coconut oil terhadap pertumbuhan jamur Candida albicans yang disisalah dari sampel swab vagina. JST (Jurnal Sains dan Teknol). 2017; 6(2): 209–19.
25. Gan R. Bioactivities of berberine : An update. Int J Mod Biol Med. 2012; 1(1): 48–81.
26. da Silva AR, de Andrade Neto JB, da Silva CR, Campos R de S, Costa Silva RA, Freitas DD, do Nascimento FBSA, de Andrade LND, Sampiao LS, Grangeiro TB, Magalhães HIF, Cavalcanti BC, de Moraes MO, Nobre Júnior HV. Berberine antifungal activity in fluconazole-resistant pathogenic yeasts: Action mechanism evaluated by flow cytometry and biofilm growth inhibition in Candida spp. Antimicrob Agents Chemother. 2016; 60(6): 3551–7.
27. Li D-D, Xu Y, Zhang D-Z, Quan H, Mylonakis E, Hu D-D, Li M-B, Zhao L-X, Zhu L-H, Wang Y, Jiang Y-Y. Fluconazole assists berberine to kill fluconazole-resistant Candida albicans. Antimicrob Agents Chemother. 2013; 57(12): 6016–27.
28. Al Aboody MS, Mickymaray S. Anti-fungal efficacy and mechanisms of flavonoids. Antibiot (Basel, Switzerland). 2020; 9(2): 45.